1. ALLA AKTIER
  2. NYHETER
  3. XBRANE BIOPHARMA

Xbrane Biopharma

Nyheter Xbrane Biopharma Nyheter alla bolag

Invitation to presentation of Xbrane Biopharma’s interim report January – September 2023 on November 30, 2023

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on Thursday, November 30th, 2023, at 11.00 a.m. CET. Xbrane will publish the company’s interim report January – September 2023, on Thursday, November 30, 2023, at 8.00 a.m. CET.

Martin Åmark, CEO, and Anette Lindqvist, CFO/IR, will present the interim report January – September 2023, followed by a Q&A session. The presentation will be in English. To attend, please follow the link below:

If you wish to participate via webcast, please use the link below. Via the webcast you can ask written questions.
Xbrane Biopharma Q3 Report 2023 (financialhearings.com)

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
Call Access (financialhearings.com)

Contacts

Martin Åmark, CEO
M: +46 76 309 37 77
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 27 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during the first quarter 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com  

Attachments

Invitation to presentation of Xbrane Biopharma’s interim report January – September 2023 on November 30, 2023

Datum 2023-11-28, kl 07:00
Källa MFN
Bifogade filer
Invitation to presentation of Xbrane Biopharma’s interim report January – September 2023 on November 30, 2023
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!